Arca
Skip to content
Tools
Tools

Brain metastases

Drug research and approvals for brain metastases: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 320 studies of brain metastases are recruiting on ClinicalTrials.gov, Health Canada has authorized 14 drug trials for it since 2013, and FDA has 3 approved and 7 open orphan designations naming it.

  • Recruiting worldwide: 320
  • Trials authorized in Canada: 14
  • FDA orphan approvals: 3
  • EU medicines: 0

Recruiting now

Newest posted first, of 320 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

The 10 newest of 14; search them all in Canada trials
Dec 10, 2024Evaluating outcome for brain metastases treated with stereotactic radiotherapy with dynamic petFludeoxyglucose (18F) injectionSt Josephs Health Centre LondonOngoing
Jun 23, 2022A randomized pivotal study assessing the efficacy of targeted blood-brain barrier (BBB) disruption using exablate focused ultrasound during the standard of…Perflutren /pembrolizumabInsightecPending
Sep 9, 2021A study to evaluate the safety and feasibility of mr-guided focused ultrasound and pembrolizumab treatments for brain metastases in patients with lung cancerDefinity (perflutren) / PembrolizumabInsightecPending
Mar 11, 2021Phase III trial of stereotactic radiosurgery (SRS) versus hippocampal-avoidant whole brain radiotherapy (ha-wbrt) for brain metastases from small cell lung…MemantineNrg OncologyPending
Jan 5, 2021Phase III trial of salvage stereotactic radiosurgery (SRS) or srs + hippocampal-avoidant whole brain radiotherapy (ha-wbrt) for first or second distant brain…MemantineNrg OncologyPending
Jan 2, 2020Differentiating radionecrosis from tumour progression using hybrid flt-pet/MRI in patients with brain metastases treated with stereotactic radiosurgery[18F]-FLT (3'-DEOXY-3'-fluorothymidine)University Health NetworkOngoing
Jan 2, 2020An interventional, randomized phase II study investigating the efficacy of immune checkpoint inhibitors while corticosteroid therapy is required for patients…Prednisone / DexamethasoneCross Cancer Institute - Cancer Care AlbertaOngoing
May 29, 2019A phase 2, open-label, randomized, multicenter trial of encorafenib + binimetinib evaluating a standard-dose and a high-dose regimen in patients with…Binimetinib (MEK162)/ Encorafenib (LGX818)PfizerOngoing
Apr 27, 2018A phase III trial of stereotactic radiosurgery compared with hippocampal-avoidant whole brain radiotherapy (ha-wbrt) plus memantine for 5 or more brain…MemantineCanadian Cancer Trials Group, Cancer Research Institute, Queen's UniversityOngoing
Jan 15, 2018A study to evaluate the safety and feasibility of the blood-brain barrier disruption using MRI-guided focused ultrasound in the treatment of HER2-positive…PerflutrenInsightecPending

FDA orphan designations

Approved first, then open designations, newest first
Oct 7, 2026TukysaIn combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or…Seattle Genetics, Inc.Approved
Oct 16, 2025FerabrightFor magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions…Azurity Pharmaceuticals, Inc.Approved
Apr 17, 2020TucatinibTUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or…Seattle Genetics, Inc.Approved
Nov 20, 2024AzeliragonTreatment of breast cancer brain metastasesCantex PharmaceuticalsDesignated
Mar 25, 2024Neratinib maleate TabletsTreatment of HER2-Positive Gastroesophageal Cancer with Brain MetastasesConvalife Pharmaceuticals Co., Ltd.Designated
Mar 21, 2024UtideloneTreatment of breast cancer brain metastasesBiostar Pharma, Inc.Designated
Mar 6, 2017Fixed dose combination of methimazole and liothyronineTreatment of brain metastases in patients with primary lung cancerMusli Thyropeutics Ltd.Designated
Apr 15, 2015[α′N-(2′succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg…Treatment of breast cancer patients with brain metastasesAngiochem, Inc.Designated
Jul 28, 2004EfaproxiralAdjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancerAllos Therapeutics, Inc.Designated
Jan 27, 2003Motexafin gadoliniumFor use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumorsPharmacyclics, LLCDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.